Please login to the form below

Not currently logged in
Email:
Password:

Astellas Pharma sees drop in Q2 income

Astellas reports a fall in income for the second quarter of 2011, as R&D and administrative expenses rise

Astellas Pharma, the Japanese pharmaceutical company, has posted a 36 per cent fall in net income to 25.1bn yen in the second quarter of 2011.

The company reported that net sales increase by 6 per cent to 251.6bn yen, boosted in part by its acquisition of OSI Pharmaceuticals in June 2010.

In Europe sales increased by 5 per cent in the quarter to 54.9bn yen, while Japanese sales rose by 139.3bn yen. Sales in the Americas increased by 21 per cent to 48.2bn for the quarter, while sales in Asia rose by 1.6 per cent to 9bn yen.

The company reported that second quarter R&D expenses had risen by 13 per cent to 43.5bn yen, while selling, general and administrative expenses increased by 11.5 per cent to 125.3bn yen for the quarter.

1st August 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics